GGrantIndex
← Search

DMP 777 DOSAGE IN ADULT SUBJECTS WITH CYSTIC FIBROSIS

$0M01FY2000RRNIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

Abstract

This is an industry sponsored (DuPont Merck) multi-centered dose escalating study to evalute the safety, tolerability, pharmacokenetics (PK) and pharmacodynamics (PD) of DMP 777 in adults with cystic fibrosis. Objectives are to evaluate safety, efficacy, PK and PD or multiple oral doses, administered at different doses or regimens, and to determine the dose required to sustain high-level systemic neutrophil elastase inhibition. The study theorizes that the amount of lung destruction in cystic fibrosis will be reduced if neutrophil elastase is neutralized.

View original record on NIH RePORTER →
DMP 777 DOSAGE IN ADULT SUBJECTS WITH CYSTIC FIBROSIS · GrantIndex